…, as is the stress caused by any delays. Every effort should be made to expedite their publication. Research currently takes far too long and any attempt to speed up the process is welcome. Time is a commodity those with Parkinson's do not have”.
Take home message: The best comparative study suggests that there is not much to choose between the different classes of Parkinson’s medication in terms of symptom control and quality of life in the early stages. We still need better evidence on longer term effectiveness.